Dr Reddy’s Laboratories

Dr Reddy's Q4 results: The revenue was up 15% to Rs 5,437 crore for the quarter under review

While the company's bottom line grew 10.5% annually over the 2016-17 through 2021-22 (FY22) period, it is expected to register thrice that growth rate over next two years, observes ICICI Securities

The market was expecting Tata Motors to replace DRL in the 30-share index

The company's Russian revenue was at Rs 686 crore for Q4FY22, a year-on-year growth of 70%.

The pharmaceutical giant may witness some impact due to its large exposure of the business to Russia, and CIS regions.

The acquisition of Cidmus is yet another move by drug major to widen access of healthcare professionals and patients to well-established brands

Meanwhile, local manufacturing partners have either halted or reduced production of Sputnik Light owing to low demand

US price erosion, India growth trends would be keenly tracked

The stock of the pharmaceutical company, which has a significant presence in the Russian market, has fallen below its previous low of Rs 4,135.90 touched on March 19, 2021

During the transition period, Dr Reddy's will continue to supply the product to Binnopharm Group to ensure availability in the market

Dr Reddy's Laboratories said it has launched vasopressin injection, which is used to control frequent urination, increased thirst, and loss of water caused by diabetes, in the American market.

Dr Reddy's Laboratories, marketing partner of the Russian Direct Investment Fund for the Sputnik V and Sputnik Light vaccines, has sought government approval for use of Sputnik Light as a booster shot

Dr Reddy's Laboratories on Friday said it is in discussions with the Indian drug regulator to bring Russia's Sputnik M, a COVID-19 vaccine for the 12 to18-year-old category, to India.

In a Q&A, the chairman of Dr Reddy's Laboratories dwells, among other things, on the draft R&D policy and the first-ever Global Innovation Summit of the pharma sector held last November

Nifty should be held long with the stoploss of 16,650.

For rerating, it needs sustained growth in India, recovery in US

Booster shot with Sputnik trials may also begin

The German drug maker has obtained interim injunctions against MSN Labs and Dr Reddy's Lab

Hospital industry sources claim they want assurance on shelf life of imported vaccines

DRL on Tuesday said it has launched generic Chlordiazepoxide Hydrochloride and Clidinium Bromide capsules used for treatment of stomach ulcers, irritable bowel syndrome and inflammation of the colon